<html xmlns="http://www.w3.org/1999/xhtml" xmlns="http://www.w3.org/1999/xhtml">
 <head xmlns="http://www.w3.org/1999/xhtml">
 <title xmlns="http://www.w3.org/1999/xhtml"></title>
 </head>
 <body xmlns="http://www.w3.org/1999/xhtml">
 
 Regulatory News:
 
 
 Mauna Kea Technologies MKEA MKEAY (Euronext: MKEA, 
 OTCQX: MKEAY) inventor of Cellvizio®, the multidisciplinary confocal 
 laser endomicroscopy platform, today announced the presentation of data 
 from the National French Registry on Cellvizio® procedures confirming 
 the strong performance of confocal laser endomicroscopy (CLE) in the 
 diagnosis of major gastrointestinal diseases as compared to histological 
 findings. The registry outcomes1 were disclosed in an oral 
 presentation during the Annual French-speaking Meeting on 
 Hepato-Gastroenterology and Digestive Oncology on March 24, 2017 in 
 Paris (JFHOD 2017).
 
 
 The Cellvizio National French Registry is a post-market observational 
 study sponsored by the French National Digestive Endoscopy Society 
 (SFED). The presentation at JFHOD 2017 meeting covered data from 399 
 prospective CLE-procedures performed between September 2013 and February 
 2015 at 12 participating endoscopy centers. Overall imaging quality was 
 ranked as good in 83% (331/399) of the cases, bad in only 1% (4/399) and 
 correlation factor with histology (Kappa) was equal or greater than 0.90 
 in the following 3 key indications:
 
 <ul xmlns="http://www.w3.org/1999/xhtml">
 <li xmlns="http://www.w3.org/1999/xhtml" class="bwlistitemmargb">
 Barrett Esophagus Detection and Follow-up (28% of the registry 
 cases), Kappa was 0.90 for the differentiation of normal tissues, 
 inflammatory, metaplasia and dysplastic lesions; Cellvizio allowed 
 real time biopsy guidance or impacted immediate therapeutic decision 
 in 84% of the patients
 </li>
 <li xmlns="http://www.w3.org/1999/xhtml" class="bwlistitemmargb">
 Biliary Strictures Characterization (11% of the registry 
 cases), Kappa was 0.94 for the differentiation of normal tissues, 
 inflammatory, high-grade dysplastic lesions or carcinoma ; Cellvizio 
 allowed real time biopsy guidance or impacted immediate therapeutic 
 decision in 90% of the patients
 </li>
 <li xmlns="http://www.w3.org/1999/xhtml" class="bwlistitemmargb">
 Pancreatic cysts Characterization (30% of the registry cases), 
 Kappa was 0.93 for the differentiation of serous cysts, mucinous 
 cysts, IPMN, pseudocysts or neuroendocrine tumor; Cellvizio allowed 
 real time diagnosis and impacted immediate therapeutic decision in 80% 
 of the patients. More rare cases have been observed (lymph nodes, 
 pancreatic masses, ampullomas …) in 10% of the patients.
 </li>
 </ul>
 
 The remaining indications were gastritis follow-up in 5% of the 
 patients, characterization of colorectal polyps in 11% and detection of 
 dysplastic lesions in inflammatory bowel diseases in 5% with respective 
 Kappa value of 0.78, 0.70 and 0.82.
 
 
 One serious adverse event without consequence was reported but was not 
 linked to the Cellvizio device.
 
 
 Sacha Loiseau, Ph.D., Founder and Chief Executive Officer of Mauna Kea 
 Technologies, commented, "We are proud to have supported the SFED in 
 this endeavor. The results from this large, comprehensive and 
 independent national registry confirm the expansion and ease of use of 
 our technology, the quick adoption and learning curve, and the safety 
 and the strong correlation of the Cellvizio procedure with histological 
 and pathological findings. Cellvizio clearly allows gastroenterologists 
 to make real-time therapeutic decision for improved patient management. 
 The results from this registry will provide an important data point in 
 our efforts to secure reimbursement for Cellvizio in France."
 
 
 Reference:
 
 
 1. Online published abstract: <a xmlns="http://www.w3.org/1999/xhtml" href="http://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.snfge.org%2Fcontent%2Fresultats-de-lobservatoire-national-des-pratiq&amp;esheet=51535433&amp;newsitemid=20170403006012&amp;lan=en-US&amp;anchor=http%3A%2F%2Fwww.snfge.org%2Fcontent%2Fresultats-de-lobservatoire-national-des-pratiq&amp;index=1&amp;md5=bbc8c37a0c75af5df107e7e8644c2ebc" rel="nofollow" rel="nofollow">http://www.snfge.org/content/resultats-de-lobservatoire-national-des-pratiq</a>
 
 
 About Mauna Kea Technologies
 
 
 Mauna Kea Technologies is a global medical device company focused on 
 eliminating uncertainties related to the diagnosis and treatment of 
 cancer and other diseases thanks to real time in vivo microscopic 
 visualization. The Company's flagship product, Cellvizio, has received 
 clearance to sell a wide range of applications in more than 40 
 countries, including the United States, Europe, Japan, China, Canada, 
 Brazil and Mexico.
 
 
 For more information on Mauna Kea Technologies, visit <a xmlns="http://www.w3.org/1999/xhtml" href="http://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.maunakeatech.fr%2F&amp;esheet=51535433&amp;newsitemid=20170403006012&amp;lan=en-US&amp;anchor=www.maunakeatech.com&amp;index=2&amp;md5=ba28988a270e99d80eb3e7c085613371" rel="nofollow" rel="nofollow">www.maunakeatech.com</a>
 
 
 Disclaimer
 
 
 This press release contains forward-looking statements concerning 
 Mauna Kea Technologies and its activities. Such forward looking 
 statements are based on assumptions that Mauna Kea Technologies 
 considers to be reasonable. However, there can be no assurance that the 
 anticipated events contained in such forward-looking statements will 
 occur. Forward- looking statements are subject to numerous risks and 
 uncertainties including the risks set forth in the registration document 
 of Mauna Kea Technologies registered by the French Financial Markets 
 Authority (Autorité des marchés financiers (AMF)) on June 13, 2016 under 
 number R.16-054 and available on the Company&#39;s website (<a xmlns="http://www.w3.org/1999/xhtml" href="http://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.maunakeatech.fr%2F&amp;esheet=51535433&amp;newsitemid=20170403006012&amp;lan=en-US&amp;anchor=www.maunakeatech.com&amp;index=3&amp;md5=f5519302c66ddaa2595277243203a782" rel="nofollow" rel="nofollow">www.maunakeatech.com</a>), 
 and to the development of economic situation, financial markets, and the 
 markets in which Mauna Kea Technologies operates. The forward-looking 
 statements contained in this release are also subject to risks unknown 
 to Mauna Kea Technologies or that Mauna Kea Technologies does not 
 consider material at this time. The realization of all or part of these 
 risks could lead to actual results, financial conditions, performances 
 or achievements by Mauna Kea Technologies that differ significantly from 
 the results, financial conditions, performances or achievements 
 expressed in such forward-looking statements. This press release and the 
 information it contains do not constitute an offer to sell or to 
 subscribe for, or a solicitation of an order to purchase or subscribe 
 for, Mauna Kea Technologies shares in any country.
 
 <img xmlns="http://www.w3.org/1999/xhtml" alt="" src="http://cts.businesswire.com/ct/CT?id=bwnews&amp;sty=20170403006012r1&amp;sid=benz2&amp;distro=nx&amp;lang=en"></img>View source version on businesswire.com: <a xmlns="http://www.w3.org/1999/xhtml" href="http://www.businesswire.com/news/home/20170403006012/en/" rel="nofollow" rel="nofollow">http://www.businesswire.com/news/home/20170403006012/en/</a></body></html>

Press Releases

Mauna Kea Technologies: Largest Cellvizio Study To Date Demonstrates Near Perfect Correlation with Histology in Key GI Procedures 

MKEAY

Mauna Kea Technologies: Largest Cellvizio Study To Date Demonstrates Near Perfect Correlation with Histology in Key GI Procedures


Hamilton Farms Becomes New Jersey&#39;s Smallest Cannabis Cultivator


Hamilton Farms announced today that it is delivering its inaugural harvest to dispensaries across the Garden State.


The list of dispensaries receiving

Craft Cannabis Cultivator Hamilton Farms Lands on Dispensary Shelves in New Jersey

SKYT


SkyWater Technology (NASDAQ:SKYT), the trusted technology realization partner, today announced that it intends to report its fiscal first quarter 2024 financial results following the close of the market on Wednesday,

SkyWater Technology to Announce First Quarter Financial Results on May 8th, 2024


CF Industries Holdings, Inc. (NYSE:CF), the world&#39;s largest producer of ammonia, and JERA Co., Inc. (JERA), Japan&#39;s largest energy company, today announced that they have executed a joint development agreement (JDA) to

CF Industries and JERA Announce Joint Development Agreement to Develop Greenfield Low-Carbon Ammonia Production Capacity in the United States

Penny Stocks

ASTS


Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased AST SpaceMobile, Inc.

INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of AST SpaceMobile, Inc. (ASTS) Investors

ASTS CLASS ACTION NOTICE: Glancy Prongay &amp; Murray LLP Files Securities Fraud Lawsuit Against AST SpaceMobile, Inc.

MNTR


Mentor Capital, Inc. (OTCQB:MNTR), a classic energy company, in its 2023 10-K, reported cash of $0.10 per share with no net debt versus today&#39;s share price of $0.04 per share. During 2023, the Company announced that the